Amyloidosis - A rare case report in Bangladesh
Abstract
Amyloidosis is a disorder where there is extracellular deposition of insoluble protein in different tissues and organs. AL amyloidosis is the commonest type where monoclonal immunoglobin light chain secreted by plasma cells is deposited as amyloid fibrils in tissues which can lead to multiorgan failure. This disorder is a rare and complex condition characterized by the deposition of amyloid proteins in tissues, leading to their dysfunction. The condition may be localized or systemic, with a wide range of clinical manifestations depending on the organs involved, such as the heart, kidneys, liver, gastrointestinal tract, and nervous system. We report a 50-year-old lady with multiple joint pain and multiple papulovesicular lesion around oral cavity, eye, around anus and macroglossia. She was diagnosed as a case of AL amyloidosis by clinical features and skin biopsy. She was put on oral lenalidomide and dexamethasone. This type of papulovesicular lesion is rare form of skin manifestation in AL amyloidosis. The importance of early recognition, multidisciplinary management, and improved healthcare resources in addressing rare diseases like amyloidosis in low-resource settings such as Bangladesh. Awareness campaigns and capacity building in healthcare systems are vital for timely diagnosis and intervention.
Downloads
References
. Loscalzo, Fauci, Kesper, Hauser, Longo, Jameson. Harrison’s Principle of Internal Medicine. 21st ed. Vol. 4. 878–884 p.
. Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology. 7th ed. 2004. 57.36-57.51.
. Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J. Al amyloidosis. Orphanet journal of rare diseases. 2012 Dec; 7:1-3.
. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New England Journal of Medicine. 2003 Aug 7;349(6):583-96.
. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments].
. Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology. 7th ed. 2004. 57.36-57.51.
. Duna GF, Cash JM. Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Rheumatic Disease Clinics. 1996 Feb 1;22(1):39-51.
. Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J. Al amyloidosis. Orphanet journal of rare diseases. 2012 Dec; 7:1-3.
. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. Journal of Clinical Oncology. 2011 May 10;29(14):1924-33.
. Jensen CE, Byku M, Hladik GA, Jain K, Traub RE, Tuchman SA. Supportive Care and Symptom Management for Patients with Immunoglobulin Light Chain (AL) Amyloidosis. Front Oncol [Internet]. 2022 Jun 23 [cited 2024 Oct 6]; 12:907584. Available from: www.frontiersin.org
. Baker KR, Rice L. The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012;8(3):3–7.
. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011 Jan 1;97(1):75-84.
. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American journal of hematology. 2005 Aug;79(4):319-28.
] Kumar S, Sengupta RS, Kakkar N, Sharma A, Singh S, Varma S. Skin involvement in primary systemic amyloidosis. Mediterr J Hematol Infect Dis. 2013;5(1):2–5.